Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Update

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the target of a large decline in short interest in March. As of March 15th, there was short interest totalling 64,700 shares, a decline of 28.0% from the February 28th total of 89,800 shares. Based on an average daily volume of 87,000 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.1% of the company’s stock are sold short.

Institutional Investors Weigh In On Xtant Medical

An institutional investor recently raised its position in Xtant Medical stock. Geode Capital Management LLC increased its stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 70.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 515,006 shares of the medical device company’s stock after buying an additional 212,394 shares during the quarter. Geode Capital Management LLC owned about 0.37% of Xtant Medical worth $348,000 as of its most recent SEC filing. 69.33% of the stock is owned by institutional investors.

Xtant Medical Stock Performance

NYSEAMERICAN:XTNT traded down $0.02 during trading hours on Monday, reaching $0.47. The company’s stock had a trading volume of 5,399 shares, compared to its average volume of 103,066. The company has a quick ratio of 0.88, a current ratio of 2.12 and a debt-to-equity ratio of 0.42. The stock has a market cap of $65.33 million, a P/E ratio of -3.62 and a beta of 0.35. Xtant Medical has a 12 month low of $0.33 and a 12 month high of $1.18. The firm has a 50 day simple moving average of $0.53.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.